Synthesis, Spectral Characterization, Electrochemical, Antioxidant and Antimicrobial Evaluation of 3d-Metal Complexes of 3-Mercapto-4-(Pyren-1-ylmethylene)Amino-1,2,4-Triazin-5-One

New transition metal complexes of cobalt(II), nickel(II), copper(II) and zinc(II) with new Schiff base [HLp] derived from pyrene-1-carbaldehyde and 4-Amino-3-mercapto-5-oxo-1,2,4-triazine were synthesized and characterized by elemental analysis, 1H-NMR, FT-IR, UV-Visible, ESR spectral studies, magnetic moment measurements and cyclic voltammetry. Results prove that [HLp] acts as bidentate ligand. Low conductance data reveal non-electrolytic nature of the complexes. The spectroscopic data and magnetic moment values along with elemental analytical data support octahedral geometries for Co(II), Ni(II), Zn(II) complexes and square planar geometry for Cu(II) complexes. ESR spectra of Cu(II) complexes exhibited g values trend as g∥>g⊥> ge. The nephelauxetic ratio (β) along with orbital reduction factors (K values) report the covalent nature of the metal-ligand bonds in complexes. Thermal analysis was also carried out to propose the composition of complexes and to determine their thermal stability. Coats-Redfern method was employed to evaluate some kinetic parameters of thermal degradation processes. In vitro antimicrobial properties of all synthesized compounds were investigated. After assessing the inhibition zones, metal complexes have been found more antimicrobial active than the Schiff base against both bacterial as well as fungal strains. Metal complexes also showed remarkable fluorescence and antioxidant properties.</p

PCR amplified products of IL1RN genes VNTR polymorphism. A. Lane 1

<p>∶50 bp DNA ladder; <b>Lane 2</b>: <i>IL1RN1</i>/<i>IL1RN1</i>; <b>Lane 3</b>: <i>IL1RN1/IL1RN4</i>, <b>Lane 4: </b><i>IL1RN2/IL1RN2</i><b>, Lane5: </b><i>IL1RN4/IL1RN2</i>. <b>B. Lane 1</b>: puc/hinf1 DNA ladder; <b>Lane 2: </b><i>IL1RN1/IL1RN1</i><b>, Lane 3: </b><i>IL1RN2/IL1RN3</i><b>, Lane 4: </b><i>IL1RN1/IL1RN1</i><b>, Lane5: </b><i>IL1RN1/IL1RN2</i>, <b>Lane 6: </b><i>IL1RN1/IL1RN6</i><b>, Lane 7: </b><i>IL1RN2/IL1RN2</i>.</p

Distribution of VNTR of <i>IL1RN</i> genotypes and alleles among infertile patients and fertile controls.

<p>Note: OR =  odds Ratio; CI = 95% confidence interval.</p>*<p>Significant p-value;</p>#<p>Controls <i>vs.</i> (1), (2), (3), (1+2+3).</p>##<p>Rare genotypes contain alleles 3, 4, or 6.</p><p>There is no simple link between the number of repeats and the number of the allele.</p

Natural male contraceptive: phytochemical investigation and anti-spermatogenic activity of <i>Pistia stratiotes</i> Linn.

<div><p>This work is an attempt to explore the anti-spermatogenic activity of <i>Pistia stratiotes</i> and to investigate it as a male contraceptive. The prepared extracts were screened for the presence of alkaloids, glycosides, steroids, flavonoids, saponin and phenolic compounds. To assess the anti-spermatogenic activity, mice were orally administered with the various extracts of <i>P. stratiotes</i> (dose: 100 and 200 mg/kg body weight/day, for 45 days) and the most active, ethanolic extract was subjected to the isolation of phytoconstituent responsible for the activity. Diethyl ether fraction of ethanolic extract was taken to isolate a saponin, sitosterol-3-<i>O</i>-[2,4-di-<i>O</i>-acetyl-6-<i>O</i>-stearyl-β-d-glucopyranoside]. Anti-spermatogenic activity of the isolated saponin was evaluated at a dose of 50 mg/kg body weight/day, for 45 days. The treatment caused significant decrease (<i>P</i> < 0.01) in the weight of reproductive organs (testis, epididymis and seminal vesicle). The sperm count, sperm viability and serum testosterone levels were significantly lowered compared with that of the control group.</p></div

Funnel plot of precision by log odds ratio showing the absence of publication bias.

<p>Funnel plot of precision by log odds ratio showing the absence of publication bias.</p

Distribution and comparison of various clinical parameters between hyper- and normo-androgenic groups.

<p>Distribution and comparison of various clinical parameters between hyper- and normo-androgenic groups.</p

PRISMA flow diagram.

<p>The flow diagrams shows screening of literature and selection of studies for meta-analysis.</p

Trail sequence analysis of the studies included in the meta-analysis.

<p>Trail sequence analysis of the studies included in the meta-analysis.</p

Results of meta-analysis (random effects model) using different analysis models.

<p>Results of meta-analysis (random effects model) using different analysis models.</p

Sensitivity analysis excluding the studies not fitting the Hardy Weinberg equilibrium.

<p>Sensitivity analysis excluding the studies not fitting the Hardy Weinberg equilibrium.</p